Babesia Duncani (WA1) Antibody IgG Test

If you have spent time outdoors along the Pacific Coast, from northern California up through Washington State, you may have been exposed to a tick-borne parasite that most doctors never test for. Babesia duncani is a microscopic organism that slips inside your red blood cells and multiplies there, triggering fever, fatigue, drenching sweats, and sometimes dangerous anemia. The standard Babesia test used across most of the country looks only for a different species, Babesia microti, and will come back completely negative even if B. duncani is actively destroying your red blood cells.

This test measures whether your immune system has built IgG antibodies (the long-lasting type your body produces after fighting off an infection) specifically against B. duncani. A positive result tells you that your body has encountered this parasite at some point. A negative result, in the right clinical setting, helps rule it out. Because this is a species-specific test, it fills a diagnostic blind spot that no other Babesia test covers.

What This Antibody Tells You (and What It Cannot)

IgG antibodies are your immune system's memory molecules. After your body fights off an infection, IgG antibodies stick around for months or even years as a record of that encounter. For B. duncani, this means a positive IgG result proves exposure but cannot, on its own, tell you whether the infection is still active or already cleared. Babesia antibodies can persist for more than a year after the parasite has been eliminated from your blood.

This distinction matters because treatment decisions should not rest on a single antibody reading. If your IgG comes back positive and you have symptoms like unexplained fever, fatigue, muscle aches, or lab findings such as low platelets or signs of red blood cell destruction, the next step is to confirm active infection with a blood smear (where a technician looks at your blood under a microscope for parasites inside red blood cells) or a PCR test (a DNA-based test that detects the parasite's genetic material directly).

Why Standard Babesia Testing Misses This Parasite

The most common Babesia species in the United States is B. microti, which is found primarily in the Northeast and upper Midwest. The standard antibody test used nationwide is built to detect B. microti, and it does not cross-react with B. duncani at all. The reverse is also true: this B. duncani-specific test will not detect B. microti antibodies. They are entirely separate assays looking for antibodies against different organisms.

This species-specific gap is the single biggest reason B. duncani infections go undiagnosed. A person bitten by a tick in Oregon who develops classic babesiosis symptoms may have their B. microti antibody test come back negative, leading clinicians to discard the diagnosis entirely. Without ordering the B. duncani-specific test, the true cause is missed. If you live in or have traveled to the Pacific Coast and have symptoms consistent with babesiosis, this test is the only serological tool that can detect prior exposure to the West Coast species.

Babesiosis: The Disease This Test Helps Detect

Babesiosis is a malaria-like illness caused by parasites that infect red blood cells. When B. duncani enters your bloodstream through a tick bite, it invades red blood cells, multiplies inside them, and eventually bursts them open to infect more cells. This cycle of invasion and destruction produces the hallmark symptoms: high fever, chills, drenching sweats, severe fatigue, headache, muscle pain, joint pain, and loss of appetite.

Blood work during active infection often shows low platelet counts (the cells that help your blood clot), hemolytic anemia (where red blood cells are being destroyed faster than your body can replace them), and elevated liver enzymes. In severe cases, the disease can progress to life-threatening complications including kidney failure, respiratory distress, clotting problems throughout the body (called disseminated intravascular coagulation), dangerously low blood pressure, and altered mental status.

Who Is at Greatest Risk for Severe Disease

Most healthy adults who contract B. duncani will develop symptoms that, while miserable, resolve with appropriate treatment. The people at highest risk for severe or life-threatening babesiosis share a few common features: they have had their spleen removed (the spleen is a key organ for filtering infected red blood cells out of circulation), they are over 50 years old, or they have a weakened immune system from medications or other conditions.

If you fall into any of these categories and have had potential tick exposure on the West Coast, testing becomes especially important. Early detection and treatment can prevent the disease from progressing to its most dangerous stages.

Interpreting Your Results

There are no universally standardized clinical cutpoints for B. duncani IgG antibody testing. The IDSA has acknowledged that too few cases of B. duncani infection have been reported to fully validate the indirect fluorescence antibody (IFA) assay used for this species. For context, the B. microti IFA (which is better studied) uses IgG titers of 1:1024 or higher to suggest acute infection, and titers of 1:64 to 1:512 with a negative IgM to suggest past exposure. These thresholds cannot be directly applied to B. duncani because the two tests use different antigens and have not been cross-validated.

In practical terms, your result will likely be reported as either positive or negative (or with a titer value). A positive result means your immune system recognizes B. duncani antigens. The clinical significance depends entirely on your symptoms, your exposure history, and whether confirmatory testing (blood smear or PCR) supports active infection.

When Results Can Be Misleading

The biggest source of misinterpretation is the persistence of antibodies long after infection has cleared. If you were treated for B. duncani babesiosis six months ago and retest positive on IgG, that does not necessarily mean the infection is back. Antibodies can linger for over a year. The only way to distinguish a persistent antibody from a new or ongoing infection is through direct detection methods: blood smear microscopy or PCR.

Early timing is another pitfall. If you were bitten by a tick last week and already feel sick, your IgG may not have risen yet. Antibodies take time to develop, and a negative result during the first days of illness does not rule out active infection. In this scenario, blood smear or PCR is far more useful than serology.

Sample handling also matters. Blood that is severely fatty (hyperlipemic) or that has had red blood cells burst during collection (hemolyzed) can interfere with the assay. Serum should be separated from the blood within a few hours and stored properly to preserve antibody integrity.

Tracking Over Time

A single B. duncani IgG result is a snapshot, not a verdict. The real diagnostic power comes from paired samples: an acute-phase blood draw when you first get sick, followed by a convalescent draw two to four weeks later. If your IgG titer rises fourfold or more between the two draws, that pattern strongly supports a recent, active infection rather than a leftover antibody from the past.

If you are being treated for confirmed babesiosis, serial testing can also help track your immune response over time. A steadily declining titer after treatment is reassuring. A titer that stays elevated or rises again may prompt your clinician to investigate whether the parasite has persisted, particularly if you are immunocompromised, which raises the risk of relapsing infection.